AGAMREE (Vamorolone), whose development at ReveraGen Biopharma was supported by CureDuchenne, has been approved in the United Kingdom (UK) for individuals with Duchenne aged 4 years and older. The Medicines Healthcare products Regulatory Agency (MHRA) recognized not just the efficacy of AGAMREE, but also clinical benefits with regards to preserving bone health and maintaining growth compared to standard corticosteroids. Santhera Pharmaceuticals is planning on having AGAMREE available in the UK in the second half of 2024. AGAMREE was also approved in the US and in Europe in 2023.
CureDuchenne Webinar with Dyne Therapeutics | Advancing the Promise of FORCE to Deliver for Patients
Sarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the ELEVIDYS Indication
How to Identify and Manage Fat Embolism Syndrome (FES) in Fractures
REGENXBIO Announces Completion of Enrollment in Cohort 2 and Additional Positive Interim Data in AFFINITY DUCHENNE® Trial
Make an Impact
You can advance the care, treatment and cure for Duchenne muscular dystrophy. Contributions in any amount can truly make a difference and can be credited to a fundraiser or event from the list below.Donate